Istaroxime stimulates <scp>SERCA2a</scp> and accelerates calcium cycling in heart failure by relieving phospholamban inhibition

Abstract

Istaroxime represents the first example of a small molecule that exerts a luso-inotropic effect in the failing human heart through the stimulation of SERCA2a ATPase activity and the enhancement of Ca(2) (+) uptake into the SR by relieving the PLB inhibitory effect on SERCA2a in a cAMP/PKA independent way.